中国飞鹤以创新为驱动力，深入推进“脑发育战略”，通过不断优化产品组合，覆盖从婴儿到老年人的全生命周期，助力中国乳业持续壮大，开拓新的增长空间，打造核心竞争力。On January 7, Eastern Time, Bank of America Securities published a report on the outlook for the China market in 2025, adjusting the outlook for CHINA FEIHE (06186) and raising the Target Price for CHINA FEIHE Stocks from HK$4.5 to HK$6.5, upgrading the rating from 'Neutral' to 'Buy'.
Bank of America Securities raised the estimated EPS for Feihe from 2024 to 2026 by 4-6%, listing supporting factors including improved penetration of product sales channels, bullish outlook on product profitability certainty, a commitment to continuously enhance shareholder returns, and potential new supportive policies in China providing additional upside space for long-term growth.
Feihe previously announced its mid-year performance for 2024, with revenue of 10.095 billion yuan and net income of 1.912 billion. It also declared a mid-term dividend of 1.353 billion, with a mid-term cash dividend ratio of about 70%, compared to about 60% in the same period last year, reflecting the company's confidence in long-term growth.
CHINA FEIHE drives innovation, deeply advancing the "Brain Development Global Strategy," continuously optimizing the product portfolio to cover the entire life cycle from infants to the elderly, supporting the continuous growth of China's dairy industry, exploring new growth spaces, and building core competitiveness.
